ATE414509T1 - Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform - Google Patents

Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform

Info

Publication number
ATE414509T1
ATE414509T1 AT00117629T AT00117629T ATE414509T1 AT E414509 T1 ATE414509 T1 AT E414509T1 AT 00117629 T AT00117629 T AT 00117629T AT 00117629 T AT00117629 T AT 00117629T AT E414509 T1 ATE414509 T1 AT E414509T1
Authority
AT
Austria
Prior art keywords
tableted
methoxy
many individual
dose form
individual units
Prior art date
Application number
AT00117629T
Other languages
English (en)
Inventor
Pontus John Arvid Bergstrand
Kurt Ingmar Loevgren
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26662095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE414509(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9402432A external-priority patent/SE9402432D0/xx
Priority claimed from SE9402433A external-priority patent/SE9402433D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE414509T1 publication Critical patent/ATE414509T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
AT00117629T 1994-07-08 1995-06-07 Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform ATE414509T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9402432A SE9402432D0 (sv) 1994-07-08 1994-07-08 New pharmaceutical dosage form
SE9402433A SE9402433D0 (sv) 1994-07-08 1994-07-08 New oral pharmaceutical dosage form

Publications (1)

Publication Number Publication Date
ATE414509T1 true ATE414509T1 (de) 2008-12-15

Family

ID=26662095

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95926054T ATE206044T1 (de) 1994-07-08 1995-06-07 Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i)
AT00117629T ATE414509T1 (de) 1994-07-08 1995-06-07 Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95926054T ATE206044T1 (de) 1994-07-08 1995-06-07 Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i)

Country Status (41)

Country Link
US (1) US5817338A (de)
EP (2) EP1078628B1 (de)
JP (1) JP3350054B2 (de)
KR (1) KR100384960B1 (de)
CN (1) CN1138534C (de)
AT (2) ATE206044T1 (de)
AU (1) AU695966B2 (de)
BR (2) BR9506018A (de)
CA (1) CA2170647C (de)
CY (1) CY2254B1 (de)
CZ (1) CZ289804B6 (de)
DE (4) DE69535889D1 (de)
DK (2) DK1078628T3 (de)
DZ (1) DZ1906A1 (de)
EE (1) EE03305B1 (de)
ES (2) ES2100142T3 (de)
FI (1) FI122017B (de)
GR (1) GR970300014T1 (de)
HK (1) HK1008300A1 (de)
HR (1) HRP950349B1 (de)
HU (1) HUT75775A (de)
IL (1) IL114450A (de)
IS (1) IS4327A (de)
MA (1) MA23607A1 (de)
MX (1) MX9600857A (de)
MY (1) MY112915A (de)
NO (1) NO314125B3 (de)
NZ (1) NZ289948A (de)
PL (1) PL180395B1 (de)
PT (2) PT723436E (de)
RU (2) RU2531553C2 (de)
SA (1) SA95160091B1 (de)
SI (2) SI0723436T1 (de)
SK (1) SK283626B6 (de)
TN (1) TNSN95075A1 (de)
TR (1) TR199500821A2 (de)
TW (1) TW450813B (de)
UA (1) UA41946C2 (de)
WO (1) WO1996001623A1 (de)
YU (1) YU49236B (de)
ZA (1) ZA955548B (de)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
ES2100142T3 (es) * 1994-07-08 2002-03-01 Astrazeneca Ab Forma de dosificacion en tabletas i constituida por unidades multiples.
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6279736B1 (en) 1995-04-19 2001-08-28 Capitol Specialty Plastics, Inc. Barrier pack having an absorbing agent applied to the interior of the pack
PT859612E (pt) * 1995-09-21 2003-10-31 Pharma Pass Ii Llc Composicao farmaceutica contendo um omeprazol acid-labil e um processo para a sua preparacao
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
DE69729950T2 (de) * 1996-11-06 2005-07-28 Wockhardt Europe Ltd. Arzneimittel-Zuführsystem mit verzögerter Freisetzung für säurelabile Arzneistoffe
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
NZ336251A (en) * 1997-01-06 2001-01-26 Pfizer Composition comprising a core layer (active ingredient, hydroxypropyl cellulose and microcrystalline cellulose), an inner layer (such as hydroxypropylmethyl cellulose, polyvinyl pyrolidore and lubricants; magnesium stearate or talc), an outer layer (hydroxypropylmethyl and hydroxypropyl cellulose)
CZ291842B6 (cs) * 1997-03-13 2003-06-18 Hexal Ag Farmaceutická formulace
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6221402B1 (en) 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
HUP0100043A2 (hu) * 1997-12-08 2001-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Savérzékeny hatóanyagot tartalmazó új gyógyszerforma
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
EP1004305B1 (de) * 1998-04-20 2011-09-28 Eisai R&D Management Co., Ltd. Stabilisierte zusammenstellungen die benzimidazole enthalten
PT1121103E (pt) * 1998-05-18 2007-02-28 Takeda Pharmaceutical Comprimidos de desintegração oral compreendendo um benzimidazole
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
JP3926936B2 (ja) * 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
WO2000074654A1 (en) 1999-06-07 2000-12-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
JP4081273B2 (ja) 1999-10-20 2008-04-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンズイミダゾール系化合物安定化方法
CA2290893C (en) 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
ATE297194T1 (de) * 1999-12-16 2005-06-15 Medinfar Produtos Farmaceutico Neue stabile mehreinheitliche substituierte benzimidazole enthaltende pharmazeutische präparate
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
CN100335040C (zh) 2000-12-07 2007-09-05 奥坦纳医药公司 含有酸敏感型活性成分的快速崩解片剂
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
JP4705747B2 (ja) * 2001-05-30 2011-06-22 ユーロセルティック ソシエテ アノニム 薬剤組成物
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
WO2003007917A1 (en) * 2001-07-16 2003-01-30 Astrazeneca Ab Pharmaceutical formulation comprising a proton pump inhibitor and antacids
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
JP2005529059A (ja) 2001-09-28 2005-09-29 マクニール−ピーピーシー・インコーポレイテッド 改質した放出用の投薬形態
ES2198195B1 (es) * 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
PT1487818E (pt) 2002-03-05 2007-07-18 Astrazeneca Ab Sais de alquilamónio de omeprazole e esomeprazole
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US7732474B2 (en) * 2002-08-02 2010-06-08 Ratiopharm, Gmbh Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
CA2503150A1 (en) * 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
US20040185119A1 (en) * 2003-02-26 2004-09-23 Theuer Richard C. Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
EP2112920B1 (de) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Protonenpumpeninhibitoren enthaltende kapseln, die verschieden aufgebaute untereinheiten zur verzögerten wirkstofffreisetzung enthalten
US20070053981A1 (en) * 2003-07-11 2007-03-08 Eva Blychert Solid composition comprising a proton pump inhibitor
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005018640A1 (en) * 2003-08-20 2005-03-03 The Procter & Gamble Company Kit for treatment of upper gastrointestinal tract conditions
WO2005020954A2 (en) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005046634A2 (de) * 2003-11-14 2005-05-26 Siegfried Generics International Ag Magensaftresistente verabreichungsform
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1753405A4 (de) * 2004-06-10 2008-09-17 Glatt Air Tech Inc Pharmazeutische formulierung mit kontrollierter freisetzung
CA2570796A1 (en) * 2004-06-15 2006-01-05 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of benzimidazole compounds
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
EP1916994B1 (de) * 2004-06-29 2013-12-11 Takeda Pharma A/S Herstellung einer pharmazeutischen zusammensetzung mit schneller freisetzung aus wasserunlöslichen arzneimitteln und mit dem erfindungsgemässen verfahren erhaltene pharmazeutische zusammensetzungen
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
EP1621187A1 (de) * 2004-07-26 2006-02-01 AstraZeneca AB Pharmazeutische multipartikuläre Tablettenzubereitungen und Prozess zu ihrer Herstellung
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006045152A1 (en) * 2004-10-29 2006-05-04 Mayne Pharma International Pty Ltd Improved tabletting process
GB0427455D0 (en) * 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
EP1830822A1 (de) * 2004-12-24 2007-09-12 LEK Pharmaceuticals D.D. Stabile pharmazeutische zusammensetzung mit einer wirksubstanz in form einer festen lösung
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2007008305A1 (en) * 2005-07-08 2007-01-18 Cherng-Ju Kim Asymmetrically coated tablet
ES2278511B1 (es) * 2005-07-28 2008-06-16 Laboratorios Almirall S.A. Comprimidos con perfil de disolucion mejorado.
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
US9440003B2 (en) * 2005-11-04 2016-09-13 Boston Scientific Scimed, Inc. Medical devices having particle-containing regions with diamond-like coatings
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
BRPI0619158A2 (pt) 2005-12-05 2011-09-20 Astrazeneca Ab processo para preparar forma que não que não seja sal de esomeprazol, composto, formulação farmacêutica, e, método de tratamento
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
TR201816133T4 (tr) 2006-04-04 2018-11-21 Kg Acquisition Llc Bi̇r anti̇platelet ajan ve bi̇r asi̇t i̇nhi̇bi̇törü i̇çeren oral dozaj formlari.
EP2012756A4 (de) * 2006-04-20 2013-01-23 Inventia Healthcare Private Ltd Zusammensetzungen mit mehreren einheiten
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US9023400B2 (en) * 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
CA2654402A1 (en) * 2006-06-01 2007-12-06 Adel Penhasi Multiple unit pharmaceutical formulation
US7713549B2 (en) * 2006-06-30 2010-05-11 Board Of Trustees Of The University Of Arkansas Extended release perforated tablet
AU2007311493B2 (en) * 2006-10-17 2013-01-31 Ranbaxy Laboratories Limited Multiple unit tablet compositions of benzimidazole compounds
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US8352042B2 (en) * 2006-11-28 2013-01-08 The Alfred E. Mann Foundation For Scientific Research Remote controls and ambulatory medical systems including the same
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CN104069088A (zh) 2007-10-12 2014-10-01 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
JP2011512416A (ja) 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
ES2552723T3 (es) * 2008-05-06 2015-12-01 Dexcel Pharma Technologies Ltd. Formulación de bencimidazol estable
DE102008045339A1 (de) 2008-09-01 2010-03-04 Stada Arzneimittel Ag Pharmazeutisches Pellet
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
FR2959509B1 (fr) 2010-05-03 2012-07-13 Prod Chim Auxiliaires Et De Synthese Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole
CN102762198A (zh) * 2010-05-15 2012-10-31 欢腾生命科学有限公司 多单元组合物
IT1401284B1 (it) 2010-08-06 2013-07-18 Valpharma S P A Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
CA2815024A1 (en) 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
AU2012331182B2 (en) * 2011-11-02 2016-05-12 Towa Pharmaceutical Europe, S.L. Pharmaceutical composition of omeprazole
CN104519888A (zh) 2011-12-28 2015-04-15 波曾公司 用于递送奥美拉唑和乙酰水杨酸的改良组合物和方法
CN103040774B (zh) * 2012-11-30 2015-03-04 上海信谊万象药业股份有限公司 埃索美拉唑镁肠溶片中埃索美拉唑镁的制粒包衣工艺
CN103044400A (zh) * 2012-12-21 2013-04-17 北京华禧联合科技发展有限公司 埃索美拉唑镁盐及其制备方法
JP5934835B2 (ja) * 2013-03-08 2016-06-15 富士フイルム株式会社 腸溶性細粒及び医薬組成物
EP2929885A1 (de) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmazeutische kombinationen von rivaroxaban und protonenpumpenhemmern
EP2933002A1 (de) 2014-04-11 2015-10-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmazeutische kombinationen von dabigatran und protonenpumpeninhibitoren
US20170182070A1 (en) 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
MX2017004473A (es) * 2014-10-08 2017-10-12 Synthetic Biologics Inc Formulaciones de betalactamasa y usos de las mismas.
CN104586809A (zh) * 2015-01-08 2015-05-06 浙江亚太药业股份有限公司 一种埃索美拉唑镁微丸肠溶片及制备方法
WO2016162754A1 (en) 2015-04-07 2016-10-13 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions for minocycline
EP3288556A4 (de) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Oral zerfallende zusammensetzungen
US10076494B2 (en) * 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10137111B2 (en) 2016-08-11 2018-11-27 Adamis Pharmaceuticals Corporation Drug compositions comprising an anti-parasitic and proton pump inhibitor
WO2018065953A1 (en) * 2016-10-06 2018-04-12 Jubilant Generics Limited Pharmaceutical suspension dosage form of benzimidazole compounds and process of preparation thereof
KR101877350B1 (ko) 2016-10-28 2018-08-09 한미약품 주식회사 에스오메프라졸 함유 복합 캡슐제 및 그 제조방법
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)
EP3720844A4 (de) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation Arzneimittelzusammensetzungen
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
WO2020040438A1 (ko) 2018-08-23 2020-02-27 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
KR102290295B1 (ko) 2019-07-26 2021-08-17 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
JPWO2021153525A1 (de) 2020-01-27 2021-08-05
KR102573842B1 (ko) 2020-02-21 2023-09-01 주식회사 종근당 방출특성이 우수한 에스오메프라졸 및 탄산수소나트륨의 약제학적 조성물
KR20210012881A (ko) 2020-02-28 2021-02-03 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
CN114569579B (zh) 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
CN115120569B (zh) * 2022-07-07 2023-11-28 江苏中邦制药有限公司 一种去除微丸间静电的方法
KR20240030479A (ko) 2022-08-31 2024-03-07 한올바이오파마주식회사 에스오메프라졸 및 제산제를 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1545612A (fr) * 1967-06-15 1968-11-15 Dausse Lab Procédé de fabrication de comprimés
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
JPS5598120A (en) * 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS5973529A (ja) * 1982-10-12 1984-04-25 Sankyo Co Ltd 被覆固形製剤の製造法
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
GB2132887A (en) * 1982-11-15 1984-07-18 Procter & Gamble Enteric-coated anti-inflammatory compositions
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
JPH0759499B2 (ja) * 1984-02-10 1995-06-28 ベンツォン ファーマ エイ／エス 拡散被覆された複合単位服用剤
US4568560A (en) * 1984-03-16 1986-02-04 Warner-Lambert Company Encapsulated fragrances and flavors and process therefor
DE3524337A1 (de) * 1985-07-08 1987-01-08 Roehm Gmbh Arzneimittelumhuellung
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4759749A (en) * 1986-05-27 1988-07-26 Level 1 Technologies, Inc. Heater for physiological fluids
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
CA2083606C (en) * 1990-06-20 2001-08-21 Arne Elof Brandstrom Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
JP3142919B2 (ja) * 1991-11-06 2001-03-07 旭化成株式会社 セルロース誘導体ラテックス及びその製法
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
NZ253999A (en) * 1992-08-05 1996-07-26 Faulding F H & Co Ltd Pelletised substained release medicament
US5330759A (en) * 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
JP3017906B2 (ja) * 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
JP3710473B2 (ja) * 1993-10-12 2005-10-26 三菱ウェルファーマ株式会社 腸溶性顆粒含有錠剤
GB2285989A (en) * 1994-01-28 1995-08-02 Merck Frosst Canada Inc Aqueous formulations for enteric coatings
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2100142T3 (es) * 1994-07-08 2002-03-01 Astrazeneca Ab Forma de dosificacion en tabletas i constituida por unidades multiples.

Also Published As

Publication number Publication date
PT723436E (pt) 2002-02-28
PT1078628E (pt) 2009-01-27
HRP950349B1 (en) 2002-06-30
FI961057A0 (fi) 1996-03-07
CZ73296A3 (en) 1996-07-17
SI1078628T1 (sl) 2009-04-30
CA2170647C (en) 2001-03-13
SK30196A3 (en) 1997-09-10
PL180395B1 (pl) 2001-01-31
HK1008300A1 (en) 1999-05-07
ES2100142T1 (es) 1997-06-16
EP1078628B1 (de) 2008-11-19
HU9600573D0 (en) 1996-05-28
EP1078628A2 (de) 2001-02-28
IS4327A (is) 1996-03-04
CN1134666A (zh) 1996-10-30
AU695966B2 (en) 1998-08-27
AU2993795A (en) 1996-02-09
FI961057A (fi) 1996-03-29
DK0723436T3 (da) 2001-11-26
DE69522921T2 (de) 2002-04-11
SI0723436T1 (en) 2002-02-28
FI122017B (fi) 2011-07-29
DE723436T1 (de) 1997-09-11
NO960950D0 (no) 1996-03-07
KR100384960B1 (ko) 2003-08-21
UA41946C2 (uk) 2001-10-15
IL114450A0 (en) 1995-11-27
ES2100142T3 (es) 2002-03-01
TNSN95075A1 (fr) 1996-02-06
DE29522419U1 (de) 2003-07-03
EE03305B1 (et) 2000-12-15
YU49236B (sh) 2004-12-31
DE69535889D1 (de) 2009-01-02
GR970300014T1 (en) 1997-05-31
NO314125B1 (no) 2003-02-03
ES2316333T3 (es) 2009-04-16
SK283626B6 (sk) 2003-10-07
EP1078628A3 (de) 2003-03-19
PL313387A1 (en) 1996-06-24
RU2160094C2 (ru) 2000-12-10
HRP950349A2 (en) 1997-06-30
MA23607A1 (fr) 1996-04-01
JPH09502739A (ja) 1997-03-18
US5817338A (en) 1998-10-06
NO960950L (no) 1996-03-07
NO314125B3 (no) 2008-12-08
DK1078628T3 (da) 2009-02-23
HUT75775A (en) 1997-05-28
JP3350054B2 (ja) 2002-11-25
ATE206044T1 (de) 2001-10-15
DE69522921D1 (de) 2001-10-31
BR9506018A (pt) 1997-09-02
CZ289804B6 (cs) 2002-04-17
WO1996001623A1 (en) 1996-01-25
ZA955548B (en) 1996-01-08
TW450813B (en) 2001-08-21
YU44895A (sh) 1998-07-10
EP0723436A1 (de) 1996-07-31
CN1138534C (zh) 2004-02-18
CA2170647A1 (en) 1996-01-25
TR199500821A2 (tr) 1996-06-21
MX9600857A (es) 1997-06-28
IL114450A (en) 1999-09-22
MY112915A (en) 2001-10-31
DZ1906A1 (fr) 2002-02-17
BR1100458A (pt) 2005-05-03
CY2254B1 (en) 2003-07-04
SA95160091B1 (ar) 2005-06-14
NZ289948A (en) 1997-07-27
RU2531553C2 (ru) 2014-10-20
EP0723436B1 (de) 2001-09-26

Similar Documents

Publication Publication Date Title
ATE414509T1 (de) Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform
DE69631981D1 (de) Lansoprazolhaltige Arzneizusammensetzung und Herstellungsverfahren
AR005280A1 (es) Forma de dosis efervescente unitaria multiple en tabletas, proceso para su fabricacion y uso de dicha forma para la fabricacion de medicamentos.
RU96107097A (ru) Составная единичная дозированная форма в виде таблетки, содержащая ингибитор протонного насоса

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1078628

Country of ref document: EP